Podcasts about rhbmp

More often than not, a surgical innovation is not the result of an overnight success, but rather the result of iterative improvements on a tool or technique that leads to better outcomes. In this episode of the BackTable MSK Podcast, we interview Dr. Jim Marino, a retired orthopedic surgeon and prolific medtech innovator. Dr. Marino gives us an inside look at his extensive career, detailing his role in orthopedic device innovation and the trials and tribulations that he faced along the way. --- SYNPOSIS Having trained in an era where joint arthroscopy was emerging, Dr. Marino had a vision to build devices for minimally invasive spine surgery that paralleled developments in peripheral joint surgery. Alongside venture capitalists, he founded the company NuVasive, and eventually Trinity Orthopedics. He discusses the COREX device, a percutaneous autologous bone harvester that rivals the use of biologics. COREX maintains the gold standard of using cancellous bone grafts and significantly decreases donor site pain. Applications for this device started with bone grafting for spinal fusion surgery, but are now expanding to foot and ankle procedures. Throughout this episode, Dr. Marino also shares valuable advice for aspiring physician innovators on maintaining a clinical practice during the entrepreneurship journey and balancing patient safety with innovative practices. --- TIMESTAMPS 00:00 - Introduction 14:34 - Reflections on Spine Innovation 25:03 - Clinical and Radiographic Evaluation 31:50 - Founding NuVasive: From Ideas to Reality 43:28 - Minimally Invasive Bone Grafting with COREX 1:00:06 - Future Applications of COREX 01:10:21 - Advice for Aspiring Physician Innovators --- RESOURCES NuVasive: https://www.nuvasive.com/ COREX Minimally Invasive Bone Harvester: https://trinityorthodevice.com/ YODA Project for rhBMP-2 safety and efficacy : https://yoda.yale.edu/about/data-holders/medtronicrhbmp-2/ Seattle Science Foundation YouTube: https://www.youtube.com/channel/UChIIig54yF9aQYvpWGe1DPg

Dr. Robert E. Marx is a retired Professor of Surgery, Chief of the Division of Oral and Maxillofacial Surgery at the University of Miami Miller School of Medicine, and Chief of Surgery at Jackson South Medical Center. He is an active lecturer on topics for oral and maxillofacial surgery throughout the United States and abroad. Dr. Marx is also the Chief Scientific Consultant for the Stem Cell Division of Lenkbar Medical Devices.He has received numerous academic and research awards including the Donald B. Osbon Award as an educator, the Harry S. Archer Award for pioneering work in oral and Maxillofacial Surgery, The Paul Bert Award for research in Hyperbaric Medicine, the William J. Gies Award for Life Long contributions to Oral and Maxillofacial Surgery, and was awarded the American Association of Oral and Maxillofacial Surgery Research Recognition Award twice. Dr. Marx is also a decorated United States Air Force Veteran serving 13 years of active duty and nine years in the reserves including service in Operation Desert Storm.  He has received numerous ribbons and citations including The Air Force Longevity Service Award, The National Defense Ribbon, Two Bronze Oak Left Clusters, The Air Force Outstanding Unit Award, The Reservist of the Year Award, and the Meritorious Service and Legion of Merit Awards. In addition to his many honors, Dr. Marx is known as the pioneer of Hyperbaric Oxygen Therapy (HBOT) and Platelet Rich Plasma (PRP).  He was also one of four principal investigators who accomplished 20 years of preclinical research and 13 years of human trials to bring recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) to a unanimous FDA approval. He was also the first practitioner to identify and alert the medical and dental professions of the bone toxic effect of bisphosphonates and RANKL inhibitors in both osteoporosis drugs and antiresorptive drugs for cancer patients. Dr. Marx has published more than 150 peer-reviewed scientific articles and 12 medical textbooks with his first edition of Oral and Maxillofacial Pathology A Rationale for Diagnosis and Treatment together with oral and maxillofacial pathologist Dr. Diane Stern, was awarded the Medical Writers “Book of the Year” Award.He is also a published author with a series of fictional books such as “Deadly Prescription, Deadly Consequences, and Deadly Game the Horns of the Rhino”; a trilogy for those that seek to be thrilled. His newly published book “Replague: The Neanderthals' Revenge,” will take you through a weave of intrigue to discover the ultimate enemy – an ancient virus. He continues to educate the world with his series on “Hot Topics in Oral and Maxillofacial Surgery, the Denver Board Review Course, OMFS Pathology Review Course in its 45th year, and “Controversies in the World” with podcast episodes for the broad-minded listener.  

Heather Wolff joined Decibel in February 2018 as the head of clinical development operations for Decibel Therapeutics. Heather is responsible for Decibel’s clinical operations, regulatory operations, medical writing and data management functions, providing leadership around the company’s development programs. She has a long track record in clinical development, with a focus on building and leading data management groups. Widely recognized as a leader in the space, she has been a key member of both large and small companies including Infinity Pharmaceuticals, Millennium Pharmaceuticals (Takeda), Accenture (ACE), Synta Pharmaceuticals and Genetics Institute (Wyeth). She played a role in successfully gaining FDA approval for Wyeth’s rhBMP-2 in the U.S. and E.U., and also facilitated the acquisition of sNDAs for Millennium’s Velcade product. Heather graduated from Skidmore College with a B.A. in English.

TThis podcast covers the JBJS issue for May 2013. Featured are articles covering: Risk Factors Associated with Deep Surgical Site Infections After Primary Total Knee Arthroplasty; Use of Erythromycin and Colistin-Loaded Cement in TKA Does Not Reduce Incidence of Infection; recorded commentary by Dr. Roberts; Adverse Tissue Reactions from Modular Neck Corrosion in THA; The Effect of rhBMP-2 in Single-Level Posterior Lumbar Interbody Arthrodesis; recorded commentary by Dr. Bolesta.

TThis podcast covers the JBJS issue for May 2013. Featured are articles covering: Risk Factors Associated with Deep Surgical Site Infections After Primary Total Knee Arthroplasty; Use of Erythromycin and Colistin-Loaded Cement in TKA Does Not Reduce Incidence of Infection; recorded commentary by Dr. Roberts; Adverse Tissue Reactions from Modular Neck Corrosion in THA; The Effect of rhBMP-2 in Single-Level Posterior Lumbar Interbody Arthrodesis; recorded commentary by Dr. Bolesta.

This podcast covers the JBJS issue for August 2011. Featured are articles covering: Comparison of Minimally Invasive Direct Anterior Versus Posterior THA Based on Inflammation and Muscle Damage Markers; recorded commentary by Dr. Manner; Patellar Resurfacing in TKR - Five-Year Clinical and Economic Results of a Large Randomized Controlled Trial; recorded commentary by Dr. Gross; Lumbar Plexus Anatomy within the Psoas Muscle - Implications for the Transpsoas Lateral Approach to the L4-L5 Disc; Alterations in Recovery from Spinal Cord Injury in Rats Treated with rhBMP-2 for Posterolateral Arthrodesis.

This podcast covers the JBJS issue for August 2011. Featured are articles covering: Comparison of Minimally Invasive Direct Anterior Versus Posterior THA Based on Inflammation and Muscle Damage Markers; recorded commentary by Dr. Manner; Patellar Resurfacing in TKR - Five-Year Clinical and Economic Results of a Large Randomized Controlled Trial; recorded commentary by Dr. Gross; Lumbar Plexus Anatomy within the Psoas Muscle - Implications for the Transpsoas Lateral Approach to the L4-L5 Disc; Alterations in Recovery from Spinal Cord Injury in Rats Treated with rhBMP-2 for Posterolateral Arthrodesis.

Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) is a morphogen with the ability to induce the formation of cartilage and new bone. In the product currently on the market for some special orthopaedic indications, rhBMP-2 is implanted by invasive surgery in combination with a suitable carrier which enables a sustained release and a prolonged presence of the morphogen at the site of action - prerequisites for an optimal therapeutic effect. The aim of the present work was to develop a sustained releasing “carrier-free”, injectable formulation that overcomes the necessity of invasive surgery and has the potential to expand the indications of rhBMP-2. Based on the principle of controlled precipitation, a microparticulate formulation was developed. Beside physicochemical characterisations of the microparticles, the integrity of rhBMP-2 in the precipitated state and after redissolution was demonstrated and the potential of precipitation to prevent degradation was elucidated. The ability of the microparticle formulation to deliver rhBMP-2 in a sustained manner was tested in-vitro and the efficacy of the aqueous protein suspension to augment bone density was examined in an animal model.